AU592322B2 - Physiological means of enhancing transdermal delivery of drugs - Google Patents

Physiological means of enhancing transdermal delivery of drugs Download PDF

Info

Publication number
AU592322B2
AU592322B2 AU49685/85A AU4968585A AU592322B2 AU 592322 B2 AU592322 B2 AU 592322B2 AU 49685/85 A AU49685/85 A AU 49685/85A AU 4968585 A AU4968585 A AU 4968585A AU 592322 B2 AU592322 B2 AU 592322B2
Authority
AU
Australia
Prior art keywords
transdermal delivery
delivery system
anticholinergic agent
pharmaceutically active
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU49685/85A
Other languages
English (en)
Other versions
AU4968585A (en
Inventor
Nicholas Bodor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Key Pharmaceuticals Inc
Original Assignee
Key Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Key Pharmaceuticals Inc filed Critical Key Pharmaceuticals Inc
Publication of AU4968585A publication Critical patent/AU4968585A/en
Application granted granted Critical
Publication of AU592322B2 publication Critical patent/AU592322B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU49685/85A 1984-10-11 1985-10-09 Physiological means of enhancing transdermal delivery of drugs Ceased AU592322B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65991984A 1984-10-11 1984-10-11
US659919 1984-10-11

Publications (2)

Publication Number Publication Date
AU4968585A AU4968585A (en) 1986-05-02
AU592322B2 true AU592322B2 (en) 1990-01-11

Family

ID=24647370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49685/85A Ceased AU592322B2 (en) 1984-10-11 1985-10-09 Physiological means of enhancing transdermal delivery of drugs

Country Status (15)

Country Link
EP (1) EP0198034B1 (enExample)
JP (1) JPS62500523A (enExample)
KR (1) KR930009787B1 (enExample)
AU (1) AU592322B2 (enExample)
CA (1) CA1264033A (enExample)
DE (1) DE3583234D1 (enExample)
DK (1) DK269986A (enExample)
FI (1) FI862493A0 (enExample)
GR (1) GR852469B (enExample)
IE (1) IE59291B1 (enExample)
IL (1) IL76635A0 (enExample)
MY (1) MY100471A (enExample)
NO (1) NO862321L (enExample)
NZ (1) NZ213753A (enExample)
WO (1) WO1986002272A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1705319A1 (ru) * 1987-10-23 1992-01-15 Всесоюзный Научно-Исследовательский Институт Биотехнологии Состав полимерной диффузионной матрицы дл трансдермального введени лекарственных веществ
US6395757B1 (en) * 1998-08-31 2002-05-28 Arthur M. Bobrove Method for treating hot flashes in humans
CA2461696A1 (en) * 2001-09-26 2003-04-03 Alison B. Lukacsko Compositions and methods for inhibiting eccrine perspiration in humans
BRPI0519481A2 (pt) 2004-12-27 2009-02-03 Beiersdorf Ag glicopirrolato em preparaÇÕes cosmÉticas
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
NZ710740A (en) 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US376886A (en) * 1888-01-24 Joseph beeakley holder
US3767786A (en) * 1961-04-20 1973-10-23 Procter & Gamble Inhibiting perspiration with scopolamine esters
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
NL8104929A (nl) * 1980-11-12 1982-06-01 Alza Corp Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan.
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer

Also Published As

Publication number Publication date
EP0198034B1 (en) 1991-06-12
NZ213753A (en) 1988-09-29
FI862493A7 (fi) 1986-06-11
IE59291B1 (en) 1994-02-09
KR930009787B1 (ko) 1993-10-11
KR870700364A (ko) 1987-12-28
EP0198034A1 (en) 1986-10-22
GR852469B (enExample) 1986-02-12
JPS62500523A (ja) 1987-03-05
IE852491L (en) 1986-04-11
NO862321L (no) 1986-08-07
FI862493A0 (fi) 1986-06-11
MY100471A (en) 1990-10-15
CA1264033A (en) 1989-12-27
WO1986002272A1 (en) 1986-04-24
DK269986D0 (da) 1986-06-09
NO862321D0 (no) 1986-06-10
DK269986A (da) 1986-08-11
AU4968585A (en) 1986-05-02
DE3583234D1 (de) 1991-07-18
IL76635A0 (en) 1986-02-28

Similar Documents

Publication Publication Date Title
Chabicovsky et al. Pharmacology, toxicology and clinical safety of glycopyrrolate
AU606093B2 (en) Penetration enhancers for transdermal delivery of systemic agents
US5691365A (en) Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
Stack et al. Monoamine oxidase inhibitors and anaesthesia: a review
DE602004012403T2 (de) Zusammensetzungen zur beeinflussung des gewichtsverlusts
KR102424270B1 (ko) 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템
CH667393A5 (de) Pharmazeutische zusammensetzung zur transdermalen verabreichung von basis-arzneimitteln von hoher eigenen spezifischen aktivitaet sowie mittel zu deren verabreichung.
DOMINO et al. Effects of narcotic analgesic agonists and antagonists on rat brain acetylcholine
Patrick et al. Increase in rat striatal extracellular dopamine and vacous chewing produced by two σ receptor ligands
Guyenet et al. Role of excitatory amino acids in rat vagal and sympathetic baroreflexes
JPH01502191A (ja) ２つのヘテロ原子を含んだヘテロ環式化合物を含む組成物および方法
Choi et al. Opioids and non-opioid enantiomers selectively attenuate N-methyl-D-aspartate neurotoxicity on cortical neurons
CN102085198B (zh) 透皮给药系统
CN101675926A (zh) 止痛剂和使用方法
Jönsson Pharmacological blockade of amphetamine effects in amphetamine dependent subjects
US5616580A (en) Pharmacological composition for preventing neurotoxic side effects of NMDA antagonists
CA2192938A1 (en) A method for treating pain and brain perfusion abnormalities
CN101573334A (zh) 用于治疗中枢神经系统障碍的多介质转运体抑制剂
Papke et al. Activation and inhibition of rat neuronal nicotinic receptors by ABT‐418
DE60122015T2 (de) Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz
Conway et al. Interaction of beta adrenergic agonists and antagonists with brain beta adrenergic receptors in vivo.
Ding et al. Comparative studies of epibatidine derivatives [18F] NFEP and [18F] N-methyl-NFEP: kinetics, nicotine effect, and toxicity
AU659941B2 (en) Agents for treating substance abuse disorders
EP0198034B1 (en) Physiological means of enhancing transdermal delivery of drugs
Modell et al. Dopaminergic activity of the antimuscarinic antiparkinsonian agents